Breaking News Instant updates and real-time market news.

C

Citi

$48.61

0.14 (0.29%)

, JBLU

JetBlue

$17.84

-0.38 (-2.09%)

08:07
10/17/16
10/17
08:07
10/17/16
08:07

Citi announces JetBlue as 'ThankYou Points' transfer partner

Citi (C) announced eligible U.S. cardmembers can now transfer an unlimited number of their "ThankYou Points" to JetBlue (JBLU) TrueBlue points at a rate of 1.25-to-1 for Citi Premier and Prestige cardmembers and 2-to-1 for Citi Preferred cardmembers.

C

Citi

$48.61

0.14 (0.29%)

JBLU

JetBlue

$17.84

-0.38 (-2.09%)

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

C Citi
$48.61

0.14 (0.29%)

10/11/16
COMP
10/11/16
INITIATION
Target $39
COMP
Sell
Citi initiated with a Sell at Compass Point
Compass Point analyst Charles Peabody initiated Citi with a Sell and a $39 price target saying earnings continue to look week combined with soft international and capital markets.
10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
GSCO
09/16/16
DOWNGRADE
GSCO
Neutral
Citi downgraded to Neutral from Buy at Goldman
Goldman analyst Richard Ramsden downgraded Citi to Neutral and lowered his price target on the shares to $50 from $52. The analyst said Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. Ramsden's analysis suggests growth in higher return businesses, such as credit cards and wealth management, and expense discipline will not be enough to increase ROE all the way to its 10% target. Citi remains a capital returns story, constrained by the utilization of deferred tax assets, the analyst wrote in his report.
JBLU JetBlue
$17.84

-0.38 (-2.09%)

09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
IMPC
09/16/16
INITIATION
Target $21
IMPC
Outperform
JetBlue initiated with an Outperform at Imperial Capital
Imperial Capital analyst Michael Derchin started JetBlue Airways with an Outperform rating and $21 price target. The analyst believes Zika concerns are fully priced into the shares at current levels and that JetBlue "can hold its own in competitive battles."
04/27/16
04/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JetBlue (JBLU) upgraded to Outperform at Cowen due to the belief that April will be the low point for unit revenue. Cowen cites expectations for slower capacity growth in the second half of 2016, an improved balance sheet and upside to the new credit card agreement. 2. National Oilwell (NOV) upgraded two notches to Overweight at Morgan Stanley by analyst Ole Sloreer, who said negative catalysts are played out with the dividend cut and Sete's bankruptcy filing. The analyst said lack of further negative catalysts, a strong balance sheet, and a trough in Q2 make National Oilwell a top contrarian pick. 3. LyondellBasell (LYB) upgraded to Buy at Nomura citing key commodity products of ethylene/polyethylene and key feedstock, ethane, are approaching peak conditions in 2016 as capacity conditions will outstrip demand. 4. Michael Kors (KORS) upgraded to Overweight at Piper Jaffray by analyst Erinn Murphy, who said she now believes the brand is "holding more stable footing on a global scale." She notes Piper's teen survey highlighted Kors as the top handbag brand and that peer Coach (COH) reported solid Q3 results. 5. Stryker (SYK) upgraded to Buy at Sterne Agee CRT with analyst Gregory Chodaczek saying it deserves a premium multiple given best in space fundamentals and near-term levers to expand margins and bolster sales growth. The analyst believes current valuation is too low given its diversified product portfolio and potential of beating his revenue and earnings estimates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/27/16
COWN
04/27/16
UPGRADE
Target $24
COWN
Outperform
JetBlue upgraded to Outperform at Cowen
As reported previously, Cowen upgraded JetBlue to Outperform from Market Perform as they believe April will be the low point for unit revenue. The firm also cites expectations for slower capacity growth in the second half of 2016, an improved balance sheet, and upside to the new credit card agreement. Cowen maintained its $24 price target on JetBlue shares.

TODAY'S FREE FLY STORIES

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.